Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine for prevention of gastrointestinal complications of pulse glucocorticoid therapy in MS relapse
IRCT20250211064703N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of famotidine in multiple sclerosis (MS) and gastrointestinal conditions, sponsored by Tehran University of Medical Sciences. Started Apr 2025; status: completed.
02
Drugs
famotidine
03
Conditions
multiple sclerosis (MS)gastrointestinal conditions
Beyond the preview
Go deeper on IRCT20250211064703N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250211064703N1.